Cargando…
2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
BACKGROUND: Plazomicin, a novel aminoglycoside, is active against carbapenem-resistant Enterobacteriaceae (EB) and is not inhibited by most aminoglycoside modifying enzymes that affect gentamicin and tobramycin. We investigated the activity of plazomicin against resistant EB clinical isolates and co...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810740/ http://dx.doi.org/10.1093/ofid/ofz360.1842 |
_version_ | 1783462318379630592 |
---|---|
author | Lepak, Alexander Lepak, Alexander Grajcevci, Luriane Banach, Joyce Meyer, Katherine Chen, Derrick |
author_facet | Lepak, Alexander Lepak, Alexander Grajcevci, Luriane Banach, Joyce Meyer, Katherine Chen, Derrick |
author_sort | Lepak, Alexander |
collection | PubMed |
description | BACKGROUND: Plazomicin, a novel aminoglycoside, is active against carbapenem-resistant Enterobacteriaceae (EB) and is not inhibited by most aminoglycoside modifying enzymes that affect gentamicin and tobramycin. We investigated the activity of plazomicin against resistant EB clinical isolates and compared disk diffusion (DD) vs. gradient diffusion (GD) results. METHODS: EB isolates that were carbapenem resistant and/or resistant to both gentamicin and tobramycin were retrieved from the UW Health clinical isolate repository. Each isolate was tested against plazomicin using both DD (MAST Group Ltd. Plazomicin disk 30 µg) and GD (Liofilchem Plazomicin MIC Test Strip 0.16–256 µg/mL) methods according to manufacturer instructions and using FDA clinical breakpoints for interpretation. RESULTS: 51 isolates were tested: 21 E. coli, 9 P. mirabilis, 7 E. cloacae, 6 K. pneumoniae, 3 K. oxytoca, 3 S. marcescens, 1 K. aerogenes, and 1 C. freundii. Specimen sites included: 29 blood, 8 urine, 8 soft tissue or bone, 5 intra-abdominal, and 1 sputum. Previous phenotypic AST results demonstrated 19 (37%) were CRE, of which 5 were also gentamicin and tobramycin resistant, and 32 (63%) were tobramycin and gentamicin resistant but carbapenem susceptible. Plazomicin zone diameters and minimal inhibitory concentrations (MIC) for all isolates are shown in the figure (data jittered to show frequency). There was a significant correlation between increased MIC and smaller zone diameters (Pearson coefficient −0.443, P = 0.001). However, while all 51 isolates were susceptible by DD breakpoints, only 46 (92%) were susceptible by GD breakpoints. All 5 discordant results were P. mirabilis which had an MIC of 4 µg/mL (intermediate) but zone diameters of 20–21 mm (susceptible). CONCLUSION: Concordance between plazomicin DD and GD susceptibility was only 92%. All 5 discordant results were P. mirabilis. Surveillance studies demonstrate >80% of P. mirabilis have MIC of 2–4 mg/L. Given the DD breakpoint is 16 mm, our data suggest DD was overly active in our sample set. Comparison of DD and GD to reference broth microdilution against a larger set of isolates is warranted to determine which method is optimal; however, our data suggest DD may result in categorical errors for P. mirabilis. [Image: see text] DISCLOSURES: Alexander Lepak, MD, Paratek Pharmaceuticals: Research Grant; Tetraphase Pharmaceuticals: Research Grant. |
format | Online Article Text |
id | pubmed-6810740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68107402019-10-28 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates Lepak, Alexander Lepak, Alexander Grajcevci, Luriane Banach, Joyce Meyer, Katherine Chen, Derrick Open Forum Infect Dis Abstracts BACKGROUND: Plazomicin, a novel aminoglycoside, is active against carbapenem-resistant Enterobacteriaceae (EB) and is not inhibited by most aminoglycoside modifying enzymes that affect gentamicin and tobramycin. We investigated the activity of plazomicin against resistant EB clinical isolates and compared disk diffusion (DD) vs. gradient diffusion (GD) results. METHODS: EB isolates that were carbapenem resistant and/or resistant to both gentamicin and tobramycin were retrieved from the UW Health clinical isolate repository. Each isolate was tested against plazomicin using both DD (MAST Group Ltd. Plazomicin disk 30 µg) and GD (Liofilchem Plazomicin MIC Test Strip 0.16–256 µg/mL) methods according to manufacturer instructions and using FDA clinical breakpoints for interpretation. RESULTS: 51 isolates were tested: 21 E. coli, 9 P. mirabilis, 7 E. cloacae, 6 K. pneumoniae, 3 K. oxytoca, 3 S. marcescens, 1 K. aerogenes, and 1 C. freundii. Specimen sites included: 29 blood, 8 urine, 8 soft tissue or bone, 5 intra-abdominal, and 1 sputum. Previous phenotypic AST results demonstrated 19 (37%) were CRE, of which 5 were also gentamicin and tobramycin resistant, and 32 (63%) were tobramycin and gentamicin resistant but carbapenem susceptible. Plazomicin zone diameters and minimal inhibitory concentrations (MIC) for all isolates are shown in the figure (data jittered to show frequency). There was a significant correlation between increased MIC and smaller zone diameters (Pearson coefficient −0.443, P = 0.001). However, while all 51 isolates were susceptible by DD breakpoints, only 46 (92%) were susceptible by GD breakpoints. All 5 discordant results were P. mirabilis which had an MIC of 4 µg/mL (intermediate) but zone diameters of 20–21 mm (susceptible). CONCLUSION: Concordance between plazomicin DD and GD susceptibility was only 92%. All 5 discordant results were P. mirabilis. Surveillance studies demonstrate >80% of P. mirabilis have MIC of 2–4 mg/L. Given the DD breakpoint is 16 mm, our data suggest DD was overly active in our sample set. Comparison of DD and GD to reference broth microdilution against a larger set of isolates is warranted to determine which method is optimal; however, our data suggest DD may result in categorical errors for P. mirabilis. [Image: see text] DISCLOSURES: Alexander Lepak, MD, Paratek Pharmaceuticals: Research Grant; Tetraphase Pharmaceuticals: Research Grant. Oxford University Press 2019-10-23 /pmc/articles/PMC6810740/ http://dx.doi.org/10.1093/ofid/ofz360.1842 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Lepak, Alexander Lepak, Alexander Grajcevci, Luriane Banach, Joyce Meyer, Katherine Chen, Derrick 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates |
title | 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates |
title_full | 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates |
title_fullStr | 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates |
title_full_unstemmed | 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates |
title_short | 2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates |
title_sort | 2162. comparison of plazomicin disk diffusion vs. gradient diffusion susceptibility testing results against drug-resistant clinical enterobacteriaceae isolates |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810740/ http://dx.doi.org/10.1093/ofid/ofz360.1842 |
work_keys_str_mv | AT lepakalexander 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates AT lepakalexander 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates AT grajcevciluriane 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates AT banachjoyce 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates AT meyerkatherine 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates AT chenderrick 2162comparisonofplazomicindiskdiffusionvsgradientdiffusionsusceptibilitytestingresultsagainstdrugresistantclinicalenterobacteriaceaeisolates |